Arben Biosciences

Arben Biosciences is a pre-clinical stage biotechnology company developing a proprietary platform for RNA-mediated protein restoration to treat genetic diseases. The company specializes in the engineering of transfer RNAs (tRNAs) designed to overcome nonsense mutations, which result in premature termination codons (PTCs) and truncated, non-functional proteins. By enabling the cellular machinery to read through these mutations, Arben's technology aims to restore the production of essential full-length proteins. Their primary therapeutic focus includes rare conditions such as cystic fibrosis and Duchenne muscular dystrophy. Arben's approach represents a potentially transformative modality in the field of precision medicine and RNA therapeutics.